Abstract:ABSTRACT Aims/hypothesis Insulin production and its regulated exocytosis by pancreatic islet beta cells is the major physiological mechanism controlling blood glucose concentrations. Beta cells are susceptible to failure due to genetic and environmental influences, leading to type 1 and 2 diabetes. In this work we aimed to advance understanding of the regulation of beta-cell function by identifying small molecule modulators of secretion. Methods For high-throughput screening and routine medium-throughput beta cell function assays we used mouse MIN6 beta cells stably expressing a Gaussia luciferase-linked insulin secretion reporter (InsGLuc-MIN6). We validated hit small molecules using cadaveric human islets in static culture insulin secretion assays. We measured effects on calcium influx and cAMP in MIN6 cells using Fura-2 and a bioluminescence resonance energy transfer reporter assay, respectively. Metabolism was analyzed by targeted metabolomics and Seahorse oxygen consumption assays. We measured relative gene expression and protein amounts by quantitative RT-PCR and SDS-PAGE immunoblotting, respectively. Results Through our high-throughput screen we discovered 2-(3-benzyl-2-iminobenzimidazol-1-yl)-1-thiophen-2-ylethanol (SW016789) which acutely potentiated nutrient-induced calcium influx and insulin secretion. More than 2 hours of exposure to SW016789 transiently induced the unfolded protein response of the endoplasmic reticulum and shut down of insulin secretory function. Distinct from the effects of thapsigargin, SW016789 did not affect beta cell viability or death as determined by multiplexed cytotoxicity assays and a lack of induction of cleaved PARP. This may be due in part to a more rapid induction of Hspa5 , and a lesser induction of signalling through the eIF2α kinase PERK and lack of expression of oxidative stress genes like Txnip . We determined that SW016789 acted upstream of the voltage-dependent calcium channel (VDCC) and potentiated nutrient-stimulated, but not KCl-stimulated, calcium influx. The potentiating effects of SW016789 were not due to altered metabolic pathways, mitochondrial function, or actions on G protein-coupled receptors. In chemical co-treatment experiments we discovered synergy between SW016789 and small molecule activators of protein kinase C and VDCCs, suggesting potential involvement of these pathways in the mechanism of action. Finally, chronically elevated calcium influx was required for the inhibitory impact of SW016789, as co-treatment with dihydropyridine-class VDCC inhibitors protected MIN6 beta cells and human islets from loss of function. Conclusions/interpretation These data suggest the major mechanism of action of SW016789 in beta cells is to potentiate opening of VDCCs. This activity may partially depend on protein kinase C. Beta cells under pharmacological hypersecretory conditions have the capacity to suppress their function to mitigate ER stress and avoid apoptosis. Further study of the mechanisms underlying these processes will increase understanding of beta cell function in normal and pathophysiological states. Research in context What is already known about this subject? Pharmacologic and environmental chemicals can stimulate aberrant beta cell activity. Hypersecretion of insulin from pancreatic beta cells can cause ER stress and lead to beta cell dysfunction. Defects in beta cell ER stress handling contribute to diabetes pathogenesis. What is the key question? Can the chemical tool SW016789 help uncover novel insulin secretion regulatory pathways and ER proteostasis factors? What are the new findings? SW016789 caused hypersecretion of insulin via enhanced nutrient-stimulated Ca 2+ influx followed by transient ER stress and shutdown of beta cell function without apoptosis. Blockade of voltage-dependent Ca 2+ channels protected human islets and beta cells from hypersecretion-induced dysfunction. How might this impact on clinical practice in the foreseeable future? These results have the potential to uncover beta cell ER stress mitigation factors and add support to beta cell rest strategies to preserve function.

SNAP-251–180 enhances insulin secretion by blocking Kv2.1 channels in rat pancreatic islet β-cells

The Potential DPP-4 Inhibitors from Xiao-Ke-An Improve the Glucolipid Metabolism Via the Activation of AKT/GSK-3β Pathway.

The Voltage-Gated Proton Channel Hv1 is Expressed in Pancreatic Islet Β-Cells and Regulates Insulin Secretion

Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies

Hv1 channel supports insulin secretion in pancreatic β cells through calcium entry, depolarization and intracellular pH regulation

Structural Insights into the Inhibitory Mechanism of Insulin Secretagogues on the Pancreatic ATP-Sensitive Potassium Channel.

Plasma membrane flipping of Syntaxin-2 regulates its inhibitory action on insulin granule exocytosis

GLP-1 signaling-regulated SNAP25 is involved in improved insulin secretion in diabetic GK rats after Roux-en-Y gastric bypass surgery

W2476 ameliorates β-cell dysfunction and exerts therapeutic effects in mouse models of diabetes via modulation of the thioredoxin-interacting protein signaling pathway

The Adenylyl Cyclase Inhibitor MDL-12,330A Potentiates Insulin Secretion Via Blockade of Voltage-Dependent K+ Channels in Pancreatic Beta Cells

Improved Glucose-Stimulated Insulin Secretion by Selective Intraislet Inhibition of Angiotensin II Type 1 Receptor Expression in Isolated Islets of Db/db Mice

Glucose Potentiates Beta-Cell Function by Inducing Tph1 Expression in Rat Islets

The Kv2.2 channel mediates the inhibition of Prostaglandin E2 on glucose-stimulated insulin secretion in pancreatic β-cells

Small molecule-mediated insulin hypersecretion induces transient unfolded protein response and loss of function in pancreatic islet beta cells

Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action

A Novel Protein Tyrosine Phosphatase 1b Inhibitor With Therapeutic Potential For Insulin Resistance

TXNIP inhibition in the treatment of type 2 diabetes mellitus: design, synthesis, and biological evaluation of quinazoline derivatives

Synaptotagmin-7 phosphorylation mediates GLP-1–dependent potentiation of insulin secretion from β-cells

GABA requires GLP-1R to exert its pancreatic function during STZ challenge

Carbohydrate response element‐binding protein (ChREBP) mediates decreased SNAP25 expression in islets from diabetic Goto‐Kakizaki (GK) rats

Control of insulin secretion by GLP-1